**Figure 3.** **Association of TfR1 expression with clinicopathological parameters of BC patients.** TfR1 expression was investigated in (**A**) female (*n* = 1075) and male (*n* = 12) patients, (**B**) patients with different stages of BC (normal individuals, *n* = 114; stage 1, *n* = 183; stage 2, *n* = 615; stage 3, *n* = 247; and stage 4, *n* = 20), (**C**) patients with different nodal metastasis statuses (normal individuals, *n* = 114; N0, *n* = 516; N1, *n* = 362; N2, *n* = 120; and N3, *n* = 77), (**D**) patients with different TP53 mutation statuses (normal individuals, *n* = 114; TP53-nonmutant, *n* = 698; and TP53-mutant, *n* = 334), (**E**) patients with different BC subtypes (normal individuals, *n* = 114; HER-positive, *n* = 37; luminal, *n* = 566; and triple negative, *n* = 116) and (**F**) patients with different ages (normal individuals, *n* = 114; 21–40 years, *n* = 97; 41–60 years, *n* = 505; 61–80 years, *n* = 431; and 81–100 years, *n* =54). ^{*}< 0.05, ^{**}< 0.01, ^{***}< 0.001.